Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMPNASDAQ:INCRNASDAQ:INZYNASDAQ:TSVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPImmutep$1.74+0.6%$1.77$1.32▼$2.80$254.11M1.76208,380 shs46,848 shsINCRInterCure$1.45-2.3%$1.48$1.17▼$2.62$65.90M1.2226,959 shs4,375 shsINZYInozyme Pharma$3.99+0.3%$2.24$0.72▼$6.24$257.60M2.29882,148 shs431,492 shsTSVT2seventy bio$5.00$4.99$2.29▼$5.30$266.15M1.04635,411 shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPImmutep-6.49%-2.81%-8.47%-2.81%-32.42%INCRInterCure-3.58%+0.68%-3.27%-8.64%-39.34%INZYInozyme Pharma+0.25%-0.25%+265.14%+298.00%-20.40%TSVT2seventy bio0.00%0.00%0.00%+1.01%+19.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMPImmutep1.413 of 5 stars3.51.00.00.02.70.00.0INCRInterCure0.2613 of 5 stars0.03.00.00.01.10.00.6INZYInozyme Pharma3.1848 of 5 stars4.23.00.00.02.62.50.0TSVT2seventy bio1.2158 of 5 stars1.04.00.00.00.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPImmutep 3.00Buy$7.00302.30% UpsideINCRInterCure 0.00N/AN/AN/AINZYInozyme Pharma 2.44Hold$11.75194.49% UpsideTSVT2seventy bio 2.00Hold$5.00N/ACurrent Analyst Ratings BreakdownLatest INCR, IMMP, TSVT, and INZY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/10/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)4/24/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)4/10/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/8/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/8/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPImmutep$5.14M49.44N/AN/A$1.05 per share1.66INCRInterCure$238.85M0.28N/AN/A$2.72 per share0.53INZYInozyme PharmaN/AN/AN/AN/A$2.27 per shareN/ATSVT2seventy bio$48.37M5.50N/AN/A$5.04 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)INCRInterCure-$16.83MN/A0.00∞N/AN/AN/AN/AN/AINZYInozyme Pharma-$71.17M-$1.69N/AN/AN/AN/A-88.42%-57.02%8/5/2025 (Estimated)TSVT2seventy bio-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)Latest INCR, IMMP, TSVT, and INZY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/7/2025Q1 2025TSVT2seventy bio-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million3/25/2025Q4 2024TSVT2seventy bio-$0.23-$0.31-$0.08-$0.37$12.84 million$2.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPImmutepN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPImmutep0.0118.2518.25INCRInterCure0.151.781.15INZYInozyme Pharma0.517.687.68TSVT2seventy bioN/A4.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPImmutep2.32%INCRInterCure8.34%INZYInozyme Pharma88.30%TSVT2seventy bio93.90%Insider OwnershipCompanyInsider OwnershipIMMPImmutep3.07%INCRInterCure0.24%INZYInozyme Pharma12.18%TSVT2seventy bio7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPImmutep2,021146.04 million141.09 millionOptionableINCRInterCure35045.57 million45.46 millionOptionableINZYInozyme Pharma5064.56 million57.05 millionOptionableTSVT2seventy bio44053.23 million47.87 millionOptionableINCR, IMMP, TSVT, and INZY HeadlinesRecent News About These Companies2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Western Standard LLCMay 22, 2025 | marketbeat.comStonepine Capital Management LLC Has $882,000 Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT)May 20, 2025 | marketbeat.comDimensional Fund Advisors LP Has $1.40 Million Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)May 18, 2025 | marketbeat.comMadison Avenue Partners LP Sells 1,983,327 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)May 16, 2025 | marketbeat.com2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbMay 7, 2025 | businesswire.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTApril 16, 2025 | businesswire.com2seventy Bio reports Q4 EPS (37c) vs ($1.11) last yearMarch 27, 2025 | markets.businessinsider.com2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | businesswire.comJessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) StockMarch 20, 2025 | insidertrades.com2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's WhyMarch 17, 2025 | zacks.com2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14, 2025 | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14, 2025 | businesswire.com2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in StockMarch 14, 2025 | insidertrades.comBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMarch 13, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVTMarch 12, 2025 | prnewswire.comShareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public ShareholdersMarch 11, 2025 | businesswire.com2seventy bio accepts Bristol Myers’ takeover bidMarch 11, 2025 | thepharmaletter.comBiotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition NewsMarch 11, 2025 | investorideas.comTSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to ShareholdersMarch 11, 2025 | tmcnet.com2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cashMarch 11, 2025 | markets.businessinsider.comTSVT Up on Acquisition Agreement With BMY for $286 MillionMarch 11, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative Gains3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidBy Chris Markoch | May 19, 2025View 3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidLockheed Martin: A Top Defense Pick in 2025By Jeffrey Neal Johnson | May 16, 2025View Lockheed Martin: A Top Defense Pick in 2025Salesforce’s Stock Price Presents an Opportunity to BuyBy Thomas Hughes | May 29, 2025View Salesforce’s Stock Price Presents an Opportunity to BuyAppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayBy Leo Miller | June 10, 2025View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayINCR, IMMP, TSVT, and INZY Company DescriptionsImmutep NASDAQ:IMMP$1.74 +0.01 (+0.58%) Closing price 04:00 PM EasternExtended Trading$1.73 -0.01 (-0.57%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.InterCure NASDAQ:INCR$1.45 -0.03 (-2.30%) Closing price 03:57 PM EasternExtended Trading$1.44 0.00 (-0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Inozyme Pharma NASDAQ:INZY$3.99 +0.01 (+0.25%) Closing price 04:00 PM EasternExtended Trading$3.99 0.00 (0.00%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.2seventy bio NASDAQ:TSVT$5.00 0.00 (0.00%) As of 05/13/20252seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
